Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

China

The First People's Hospital of Foshan, Foshan, Guangdong

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong

Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou